Viewing nowCombinationEmpagliflozin/Metformin Tablet 12.5/850 mg (Empagliflozin, Metformin Hydrochloride)
Empagliflozin 12.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Samjin Pharmaceutical Co., Ltd.

MFDS item code 202302699 · Approved 2023.09.11 · Insurance code 647805820
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used in conjunction with dietary and exercise therapy to help adults with type 2 diabetes to control their blood sugar levels. It is particularly suitable for those whose blood sugar control is insufficient with other treatments, and may be used cautiously in patients with cardiovascular diseases. This medication helps to improve blood sugar management, thereby reducing the risk of diabetes-related complications.
The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients who cannot achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended dose is empagliflozin 5 mg twice daily (total daily dose of 10 mg) and their current metformin dose. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching from combination therapy with empagliflozin (total daily dose of 10 mg or 25 mg) and metformin to this medicine should take the same doses of empagliflozin and metformin as they were previously taking. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If a dose of this medicine is missed, take it as soon as you remember. However, do not take a double dose at one time; skip the missed dose in such cases. Special populations Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other symptoms that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should be initiated with the individual single-ingredient products empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see Precautions for Use, 3. Patients Requiring Caution, item 1)). If renal function declines to a CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately (see Precautions for Use, 2. Patients Who Should Not Take This Medicine, item 2)). Older patients In patients aged 75 years or older, renal function and the risk of volume depletion should be taken into consideration.
This medication contains two active ingredients for the treatment of diabetes. Caution is needed because a rare side effect called lactic acidosis may occur when taking this drug. Lactic acidosis is a condition characterized by increased levels of lactate in the blood, leading to acidity, which can be life-threatening if severe. When taken in combination with other diabetes medications, the risk of hypoglycemia may increase, thus careful monitoring of blood glucose levels is essential, especially when used alongside insulin or sulfonylureas. This medication should not be used in patients with moderate to severe renal impairment, acute renal problems, severe infections, heart failure, or acute myocardial infarction. Additionally, this medication should be discontinued prior to undergoing tests that use iodinated contrast agents and should not be resumed until renal function returns to normal. It is safer for women who are pregnant or may become pregnant, and women who are breastfeeding not to take this medication. This medication may cause fluid loss, so caution is required in cases of dehydration symptoms, diarrhea, or vomiting, especially in elderly patients or those with cardiovascular diseases. During treatment, urinary and genital infections may occur, so if signs of infection appear, medical consultation is immediately necessary. Since vitamin B12 levels may decrease, patients on long-term therapy should routinely have vitamin B12 levels checked. In the case of overdose, the risk of lactic acidosis increases, so strict adherence to dosing guidelines is essential, and immediate hospital treatment should be sought if overdose is suspected. The safety and efficacy of this medication have not been established in children, so it is not recommended for those under 18 years old. The effects on driving or operating machinery are unclear, so caution is advised after taking this medication. Finally, during the course of taking this medication, regular monitoring of renal function and blood glucose levels should be performed, and any abnormal symptoms should prompt immediate consultation with a healthcare provider.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent exposure to air or moisture. It is best to maintain a storage temperature between 1 degree and 30 degrees Celsius.
Pinkish-white, convex, oval-shaped film-coated tablet
60 tablets/box [10 tablets/PTP x 6], 10 tablets/box [10 tablets/PTP x 1], 30 tablets/bottle, 60 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Samjin Pharmaceutical Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.